Toxicities of the Thrombopoietic Growth Factors

Seminars in Hematology

Volumn 47, Issue 3, 2010, Pages 289-298

  Cuker, Adam ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; ELTROMBOPAG; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; LENALIDOMIDE; NEUTRALIZING ANTIBODY; PLACEBO; RECOMBINANT MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; RECOMBINANT THROMBOPOIETIN; ROMIPLOSTIM; THROMBOPOIETIN;

ANTIBODY PRODUCTION; ARTHRALGIA; ARTICLE; CATARACT; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE MODEL; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FIBROSIS; HEART INFARCTION; HEMATOLOGIC MALIGNANCY; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INCIDENCE; LIVER TOXICITY; LUNG EMBOLISM; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NONHODGKIN LYMPHOMA; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT MONITORING; PATIENT SAFETY; PRIORITY JOURNAL; REBOUND THROMBOCYTOPENIA; RETICULIN FIBROSIS; RHINOPHARYNGITIS; SIDE EFFECT; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS;

HUMANS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; THROMBOPOIETIN;

EID: 77953889162     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2010.03.002     Document Type: Article

References (53)

1. Bussel J.B., Kuter D.J., George J.N., et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006, 355:1672-1681.
2. Kuter D.J., Bussel J.B., Lyons R.M., et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008, 371:395-403.
3. Kuter D.J., Rummel M.J., Boccia R.V., et al. Comparison of splenectomy and treatment failure incidence in nonsplenectomized patients with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care: 1-year treatment and 6-month safety follow-up [abstract]. ASH Annual Meeting Abstracts 2009, 114:679.
4. Tomiyama Y., Miyakawa Y., Okamoto S., et al. Six month treatment of low dose eltrombopag is efficacious in Japanese patients with refractory chronic immune thrombocytopenic purpura (ITP) [abstract]. ASH Annual Meeting Abstracts 2009, 114:1324.
5. Bussel J.B., Cheng G., Saleh M.N., et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007, 357:2237-2247.
6. Bussel J.B., Provan D., Shamsi T., et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomized, double-blind, placebo-controlled trial. Lancet 2009, 373:641-648.
7. Cheng G., Saleh M.N., Bussel J.B., et al. Oral eltrombopag for the long-term treatment of patients with chronic idiopathic thrombocytopenic purpura: results of a phase III double-blind, placebo-controlled study (RAISE) [abstract]. ASH Annual Meeting Abstracts 2008, 112:400.
8. Bussel J.B., Kuter D.J., Newland A., et al. Long-term efficacy and safety of romiplostim for the treatment of patients with chronic immune thrombocytopenia (ITP): 5-year update from an open-label extension study [abstract]. ASH Annual Meeting Abstracts 2009, 114:681.
9. Saleh M.N., Bussel J.B., Cheng G., et al. Long-term treatment of chronic immune thrombocytopenic purpura with oral eltrombopag: results from the EXTEND study [abstract]. ASH Annual Meeting Abstracts 2009, 114:682.
10. Kuter D.J., Bain B., Mufti G., Bagg A., Hasserjian R.P. Bone marrow fibrosis: physiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol 2007, 139:351-362.
11. Bauermeister D.E. Quantitation of bone marrow reticulin-a normal change. Am J Clin Pathol 1971, 56:24-31.
12. Beckman E.N., Brown A.W. Normal reticulin level in iliac bone marrow. Arch Pathol Lab Med 1990, 114:1241-1243.
13. Mufti G., Hasserjian R., Bain B., Kuter D., Dreiling L., Nichol J. Bone marrow reticulin in patients with immune thrombocytopenic purpura [abstract]. ASH Annual Meeting Abstracts 2006, 108:3982.
14. Kimura A., Katoh O., Hyodo H., Kuramoto A. Transforming growth factor-beta regulates growth as well as collagen and fibronectin synthesis of human marrow fibroblasts. Br J Haematol 1989, 72:486-491.
15. Terui T., Niitsu Y., Mahara K., et al. The production of transforming growth factor-beta in acute megakaryoblastic leukemia and its possible implications in myelofibrosis. Blood 1990, 75:1540-1548.
16. Ulich T.R., del Castillo J., Senaldi G., et al. Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice. Blood 1996, 87:5006-5015.
17. Yanagida M., Ide Y., Imai A., et al. The role of transforming growth factor-beta in PEG-rHuMGDF-induced reversible myelofibrosis in rats. Br J Haematol 1997, 99:739-745.
18. Kuter D.J., Mufti G., Bain B.J., Hasserjian R., Davis W., Rutstein M. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood 2009, 114:3748-3756.
19. Yan X.Q., Lacey D., Fletcher F., et al. Chronic exposure to retroviral vector encoded MGDF (mpl-ligand) induces lineage-specific growth and differentiation of megakaryocytes in mice. Blood 1995, 86:4025-4033.
20. Douglas V.K., Tallman M.S., Cripe L.D., Peterson L.C. Thrombopoietin administered during induction chemotherapy to patients with acute myeloid leukemia induces transient morphologic changes that may resemble chronic myeloproliferative disorders. Am J Clin Pathol 2002, 117:844-850.
21. Thiele J., Kvasnicka H.M., Facchetti F., Franco V., van der Walt J., Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005, 90:1128-1132.
22. Saleh M.N., Bussel J.B., Meyer O., et al. Results of bone marrow examinations in patients with chronic immune thrombocytopenic purpura treated with eltrombopag [abstract]. ASH Annual Meeting Abstracts 2009, 114:1326.
23. Cuker A., Chiang E.Y., Cines D.B. Safety of the thrombopoiesis stimulating agents for the treatment of immune thrombocytopenia. Curr Drug Saf 2010, 5:171-181.
24. Aledort L.M., Hayward C.P., Chen M.G., Nichol J.L., Bussel J. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol 2004, 76:205-213.
25. Bennett I., Forssen U., Enger C., Nelson J. Risk of thromboembolic events among patients with chronic idiopathic thrombocytopenic purpura (ITP) [abstract]. EHA Annual Meeting Abstracts 2008, 93(s1):307.
26. Hefer D., Jaloudi M. Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients: a case report and discussion of the relevant literature. Ann Hematol 2005, 84:411-415.
27. Mohren M., Markmann I., Dworschak U., et al. Thromboembolic complications after splenectomy for hematologic diseases. Am J Hematol 2004, 76:143-147.
28. Harker L.A., Hunt P., Marzec U.M., et al. Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. Blood 1996, 87:1833-1844.
29. Harker L.A., Marzec U.M., Hunt P., et al. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood 1996, 88:511-521.
30. Peng J., Friese P., Wolf R.F., et al. Relative reactivity of platelets from thrombopoietin- and interleukin-6-treated dogs. Blood 1996, 87:4158-4163.
31. Erhardt J.A., Erickson-Miller C.L., Aivado M., Abboud M., Pillarisetti K., Toomey J.R. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function. Exp Hematol 2009, 37:1030-1037.
32. Vadhan-Raj S., Murray L.J., Bueso-Ramos C., et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med 1997, 126:673-681.
33. Fanucchi M., Glaspy J., Crawford J., et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997, 336:404-409.
34. Basser R.L., Underhill C., Davis I., et al. Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer. J Clin Oncol 2000, 18:2852-2861.
35. Liebman H., Henry D., Lefrere F., et al. Long-term safety profile of romiplostim in patients with chronic immune thrombocytopenia (ITP) [abstract]. ASH Annual Meeting Abstracts 2008, 112:3415.
36. Bussel J.B., Cheng G., Saleh M.N., Vasey S., Aivado M., Brainsky A. Thromboembolic events observed in eltrombopag clinical trials in chronic immune thrombocytopenic purpura [abstract]. ASH Annual Meeting Abstracts 2009, 114:2423.
37. Cheng G., Tarantino M., Gernsheimer T., Meyer O., Brainsky A., Stone N.L. Platelet counts following eltrombopag discontinuation in patients with chronic immune thrombocytopenic purpura [abstract]. ASH Annual Meeting Abstracts 2009, 114:3517.
38. Söderberg K.C., Jonsson F., Winqvist O., Hagmar L., Feychting M. Autoimmune diseases, asthma and risk of haematological malignancies: a nationwide case-control study in Sweden. Eur J Cancer 2006, 42:3028-3033.
39. Landgren O., Engels E.A., Pfeiffer R.M., et al. Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. J Natl Cancer Inst 2006, 98:1321-1330.
40. Bennett I., Forssen U., Enger C., Nelson J. Risk of blood cancers among patients with chronic idiopathic thrombocytopenic purpura (ITP) [abstract]. EHA Annual Meeting Abstracts 2008, 93(s1):1449.
41. Erickson-Miller C., Kirchner J., Payne P., May E., Chadderton A. Eltrombopag does not enhance proliferation of non-megakaryocytic leukemia and lymphoma cell lines [abstract]. International Symposium of Myelodysplastic Syndrome Annual Meeting Abstracts 2009, 33(s1):P067.
42. Will B., Kawahara M., Luciano J.P., et al. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood 2009, 114:3899-3908.
43. Archimbaud E., Ottoman O.G., Yin J.A., et al. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood 1999, 94:3694-3701.
44. Kantarjian H, Fenaux P, Sekeres MA, et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol. Epub 2009 December 14,10.1200/JCO.2009.24.7999. Available from: http://jco.ascopubs.org.
45. Lyons R.M., Larson R.A., Kosmo M.A., et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide [abstract]. ASH Annual Meeting Abstracts 2009, 114:1770.
46. Kantarjian H., Giles F., Greenberg P., et al. Effect of romiplostim in patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine [abstract]. ASH Annual Meeting Abstracts 2008, 112:224.
47. Greenberg P.L., Garcia-Manero G., Moore M.R., et al. Efficacy and safety of romiplostim in patients with low or intermediate-risk myelodysplastic syndrome (MDS) receiving decitabine [abstract]. ASH Annual Meeting Abstracts 2009, 114:1769.
48. Nomura S., Dan K., Hotta T., Fujimura K., Ikeda Y. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood 2002, 100:728-730.
49. Kuter D.J., Goodnough L.T., Romo J., et al. Thrombopoietin therapy increases platelet yields in healthy platelet donors. Blood 2001, 98:1339-1345.
50. Li J., Yang C., Xia Y., et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001, 98:3241-3248.
51. Maddrey W.C., Cheng G., Khelif A., Wroblewski S.L., Brainsky A. Evaluation of hepatobiliary parameters during eltrombopag treatment in patients with chronic immune thrombocytopenic purpura [abstract]. ASH Annual Meeting Abstracts 2009, 114:2410.
52. McHutchison J.G., Dusheiko G., Shiffman M.L., et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007, 357:2227-2236.
53. Portielje J.E., Westendorp R.G., Kluin-Nelemans H.C., Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001, 97:2549-2554.